Overall survival and incidence of adverse events in B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: blinatumomab vs non-blinatumomab chemotherapy-- an analysis of the Center for International Blood and Marrow Transplant Research database (20170610) (Transplant outcomes among ALL in CIBMTR)

Study identification

• EU PAS number:
  EUPAS33745
• Study ID:
  34227
• Official title and acronym:
  Overall survival and incidence of adverse events in B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: blinatumomab vs non-blinatumomab chemotherapy-- an analysis of the Center for International Blood and Marrow Transplant Research database (20170610) (Transplant outcomes among ALL in CIBMTR)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Belgium

  Bulgaria

  Canada

  Croatia

  Cyprus

  Denmark

  Estonia

  Finland

  France

  Germany

  Greece

  Hungary

  Ireland

  Italy

  Latvia

  Lithuania

  Luxembourg

  Malta

  Netherlands

  Poland

  Portugal

  Romania

  Slovakia

  Slovenia

  Spain

  Sweden

  United Kingdom

  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Networks

Center for International Blood and Marrow Transplant, Milwaukee, WI

Study timelines

Date when funding contract was signed

Planned: 16/10/2018

Actual: 16/10/2018

Study start date

Planned: 13/03/2020

Actual: 18/03/2020

Data analysis start date

Planned: 01/10/2024

Actual: 01/10/2024

Date of final study report

Planned: 30/04/2025

Actual: 17/04/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)